Protein aggregation and neurodegenerative disease: Structural outlook for the novel therapeutics
Proteins: Structure, Function, and Bioinformatics · 2025-08 · 93 (8) · 1314-1329
DOI: 10.1002/prot.26561 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Proteins: Structure, Function, and Bioinformatics, online erschienen am 02.08.2023. Verfasst von Sharif Arar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, Texas, USA. Hauptthemen laut MEDLINE: Intrinsically Disordered Proteins, Alzheimer Disease, Neurodegenerative Diseases, Protein Aggregates. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 296 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, National Institute of Health USA, Mitchell Center for Neurodegenerative Diseases.
Abstract (Originalsprache)
Before the controversial approval of humanized monoclonal antibody lecanemab, which binds to the soluble amyloid‐β protofibrils, all the treatments available earlier, for Alzheimer's disease (AD) were symptomatic. The researchers are still struggling to find a breakthrough in AD therapeutic medicine, which is partially attributable to lack in understanding of the structural information associated with the intrinsically disordered proteins and amyloids. One of the major challenges in this area of research is to understand the structural diversity of intrinsically disordered proteins under in vitro conditions. Therefore, in this review, we have summarized the in vitro applications of biophysical methods, which are aimed to shed some light on the heterogeneity, pathogenicity, structures and mechanisms of the intrinsically disordered protein aggregates associated with proteinopathies including AD. This review will also rationalize some of the strategies in modulating disease‐relevant pathogenic protein entities by small molecules using structural biology approaches and biophysical characterization. We have also highlighted tools and techniques to simulate the in vivo conditions for native and cytotoxic tau/amyloids assemblies, urge new chemical approaches to replicate tau/amyloids assemblies similar to those in vivo conditions, in addition to designing novel potential drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, Texas, USA.
- Departments of Neurology, Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, Texas, USA.
- Department of Chemistry, School of Science, The University of Jordan, Amman, Jordan.
Förderung
- NIA NIH HHS
- National Institute of Health USA
- Mitchell Center for Neurodegenerative Diseases
- University of Jordan
- Fulbright Visiting Scholar Program
- Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch
Zitieren
APA
Arar, S., Haque, M. A., & Kayed, R. (2025). Protein aggregation and neurodegenerative disease: Structural outlook for the novel therapeutics. Proteins: Structure, Function, and Bioinformatics, 93(8), 1314-1329. https://doi.org/10.1002/prot.26561
Vancouver
Arar S, Haque MA, Kayed R. Protein aggregation and neurodegenerative disease: Structural outlook for the novel therapeutics. Proteins: Structure, Function, and Bioinformatics. 2025;93(8):1314-1329. doi:10.1002/prot.26561
BibTeX
@article{Arar2025,
author = {Arar, Sharif and Haque, Md Anzarul and Kayed, Rakez},
title = {Protein aggregation and neurodegenerative disease: Structural outlook for the novel therapeutics},
journal = {Proteins: Structure, Function, and Bioinformatics},
year = {2025},
volume = {93},
number = {8},
pages = {1314--1329},
doi = {10.1002/prot.26561}
}
EUVIMED